SEARCH

SEARCH BY CITATION

References

  • 1
    Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut 2001; 48: 251259.
  • 2
    Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311322.
  • 3
    O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988; 207: 373379.
  • 4
    Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110: 726734.
  • 5
    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.
  • 6
    Stone MJ, Klintmalm GB, Polter D et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: A pilot study in 20 patients. Gastroenterology 1993; 104: 196202.
  • 7
    Klintmalm GB. Liver transplantation for hepatocellular carcinoma: A registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228: 479490.
  • 8
    Cherqui D. Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998; 5: 3540.
  • 9
    Roayaie S, Frischer JS, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533539.
  • 10
    Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncog 1989; 1: 2752.
  • 11
    Vivarelli M, Bellusci R, Cucchetti A et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression? Transplantation 2002; 74: 17461751.
  • 12
    Vivarelli M, Cucchetti A, Piscaglia F et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression. Liver Transplant 2005; 11: 497503.
  • 13
    Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 17771782.
  • 14
    Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530534.
  • 15
    Maluccio M, Sharma V, Lagman M et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597602.
  • 16
    Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629635.
  • 17
    Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004; 116: 167179.
  • 18
    Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A. Microinjection of recombinant p21rho induces rapid changes in cell morphology. J Cell Biol 1990; 111: 10011007.
  • 19
    Takaishi K, Kikuchi A, Kuroda S, Kotani K, Sasaki T, Takai Y. Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility. Mol Cell Biol 1993; 13: 7279.
  • 20
    Kishi K, Sasaki T, Kuroda S, Itoh T, Takai Y. Regulation of cytoplasmic division of Xenopus embryo by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI). J Cell Biol 1993; 120: 11871195.
  • 21
    Yoshioka K, Matsumura F, Akedo H, Itoh K. Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 1998; 273: 51465154.
  • 22
    Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995; 10: 22892296.
  • 23
    Narumiya S, Ishizaki T, Watanabe N. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett 1997; 410: 6872.
  • 24
    Amano M, Chihara K, Kimura K et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997; 275: 13081311.
  • 25
    Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999; 5: 221225.
  • 26
    Sawada K, Morishige K, Tahara M et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002; 62: 60156020.
  • 27
    Kleer CG, Van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002; 160: 579584.
  • 28
    Horiuchi A, Imai T, Wang C et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003; 83: 861870.
  • 29
    Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532535.
  • 30
    Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990994.
  • 31
    Nagatoya K, Moriyama T, Kawada N et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 16841695.
  • 32
    Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000; 91: 811816.
  • 33
    Clements RT, Minnear FL, Singer HA, Keller RS, Vincent PA. RhoA and Rho-kinase dependent and independent signals mediate TGF-beta-induced pulmonary endothelial cytoskeletal reorganization and permeability. Am J Physiol Lung Cell Mol Physiol 2005; 288: L294L306.
  • 34
    Yang R, Rescorla FJ, Reilly CR et al. A reproducible rat liver cancer model for experimental therapy: Introducing a technique of intrahepatic tumor implantation. J Surg Res 1992; 52: 193198.
  • 35
    Kamada N, Calne RY. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979; 28: 4750.
  • 36
    Tashiro H, Fudaba Y, Itoh H et al. Hepatocyte growth factor prevents chronic allograft dysfunction in liver-transplanted rats. Transplantation 2003; 76: 761765.
  • 37
    Nakano Y, Monden M, Valdivia LA, Gotoh M, Tono T, Mori T. Permanent acceptance of liver allografts by intraportal injection of donor spleen cells in rats. Surgery 1992; 111: 668676.
  • 38
    Schumacher G, Oidtmann M, Rueggeberg A et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11: 14201425.
  • 39
    Cao XW, Fu ZR, Ding GS. Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721. Hepatobiliary Pancreat Dis Int 2005; 4: 269273.
  • 40
    Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999; 84: 11861193.
  • 41
    Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000; 91: 811816.
  • 42
    Yano K, Fukuda Y, Sumimoto R, Ito H, Asahara T, Dohi K. Development of a rat model for orthotopic liver transplantation for hepatocellular carcinoma. Surgery 1995; 118: 539546.
  • 43
    Roberts JP, Liu T, Freise CE et al. Liver transplantation improves survival of rats bearing hepatoma-3924A. J Surg Res 1996; 65: 5962.
  • 44
    Matsuzaki T, Murase N, Yagihashi A et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. Transplant Proc 1992; 24: 748751.
  • 45
    Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510513.
  • 46
    Genda T, Sakamoto M, Ichida T et al. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999; 30: 10271036.
  • 47
    Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001; 33: 577581.